Antigen News and Research

RSS

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd. today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme.

30 Jul 2013

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Researchers have uncovered the genetics behind what makes some people susceptible to Takayasu arteritis, a debilitating disease that can lead to poor circulation, easy tiredness in the legs and arms, organ damage and stroke.

30 Jul 2013

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Scientists develop simple, inexpensive and reliable method of detecting plague pathogen

Diagnosing the presence of Yersinia pestis, the cause of plague, may soon be easier than ever before. Scientists working with Peter Seeberger, Director at the Max Planck Institute of Colloids and Interfaces (MPIKG) in Potsdam and Professor at the Freie Universit-t Berlin, have come up with a simple, inexpensive and reliable method of detecting the bacterium.

25 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Report shows that fatal rabies virus is transmitted through transplanted kidney

An investigation into the source of a fatal case of raccoon rabies virus exposure indicates the individual received the virus via a kidney transplant 18 months earlier, findings suggesting that rabies transmitted by this route may have a long incubation period, and that although solid organ transplant transmission of infectious encephalitis is rare, further education to increase awareness is needed, according to a study in the July 24/31 issue of JAMA.

24 Jul 2013

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

Lee Wetzler, MD, an attending physician in the department of infectious diseases at Boston Medical Center and associate program director for research in the section of infectious diseases at Boston University School of Medicine (BUSM), was awarded a four-year, $2.35 million grant from the National Institutes of Health (NIH) to study the development of a gonococcal vaccine.

24 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

HistoGenetics selects MiSeq sequencing system from Illumina for use in CLIA laboratory

Illumina, Inc. today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory.

From Illumina, Inc. 22 Jul 2013

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

Qualigen, Inc., a privately owned company that provides rapid, easy to use, fully quantitative diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration for its FastPack Vitamin D Immunoassay for use on its proprietary FastPack System for the rapid determination of vitamin D status.

16 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Research roundup: Prevention task force PSA testing recommendations often ignored; Medicaid expansion for minorities; ER and aging population

The authors examined how the growing number of elderly Americans would affect the large and increasing part of non-catastrophic outpatient care. Using Census Bureau and nationally representative survey data, researchers quantified the number of ED visits that would occur if the demographic structure of the U.S. population changed, but everything else remained the same. "We observed that it is actually infants and young adults, not the elderly, who account for the largest number of ED visits," the authors write, and conclude: However, the data do predict increases in visit lengths and the likelihood of hospitalization.

12 Jul 2013

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10 issue of JAMA.

10 Jul 2013

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

Survey: 54% of men opt for prostate cancer screening test despite risks

A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study in American Journal of Preventive Medicine. Only 13 percent said they would choose not to be tested.

9 Jul 2013

ERC awards grants to boost research on vaccines

Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or 'pathogens', against which we cannot generate life-long protective immunity.

9 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Montreal researchers discover novel research model to study auto-immune diseases

A team of researchers at the IRCM, led by Dr. Javier M. Di Noia in the Immunity and Viral Infections research division, discovered a novel research model for the study of auto-immune diseases. The Montr-al scientists are the first to find a way to separate two important mechanisms that improve the quality of antibodies. This study was featured in a recent issue of The Journal of Immunology.

4 Jul 2013

Antigen News and Research

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

Researchers uncover genetics behind what makes some people susceptible to Takayasu arteritis

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Scientists develop simple, inexpensive and reliable method of detecting plague pathogen

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Report shows that fatal rabies virus is transmitted through transplanted kidney

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

HistoGenetics selects MiSeq sequencing system from Illumina for use in CLIA laboratory

Qualigen's FastPack Vitamin D Immunoassay receives FDA clearance

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

Research roundup: Prevention task force PSA testing recommendations often ignored; Medicaid expansion for minorities; ER and aging population

Soy protein supplement does not reduce recurrence of prostate cancer post radical prostatectomy

Cancer immunotherapies promise to be a new tool in fight against cancer

Survey: 54% of men opt for prostate cancer screening test despite risks

ERC awards grants to boost research on vaccines

GAPVAC aims to develop personalized therapeutic vaccines for cancer

Montreal researchers discover novel research model to study auto-immune diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News